<DOC>
	<DOCNO>NCT01079065</DOCNO>
	<brief_summary>The study conduct open-label , balance , randomize , two-treatment , two-period , two-sequence , single-dose , crossover , bioavailability study compare famotidine tablet , USP 20 mg manufacture OHM Laboratories Pepcid® AC Acid reducer famotidine tablets 20 mg ( contain famotidine 20 mg ) distribute Johnson &amp; Johnson . Merck Consumer Pharmaceutical Co. Fort Washington , PA 19034 USA fasting condition .</brief_summary>
	<brief_title>A Relative Bioavailability Study 20 mg Famotidine Tablets Under Fasting Condition</brief_title>
	<detailed_description>Following overnight fast least 10 hour , single oral dose famotidine tablet , USP 20 mg Pepcid® AC Acid reducer famotidine tablets 20 mg ( contain famotidine 20 mg ) administer period study , along 240 mL drink water ambient temperature supervision train study personnel . During course study , safety parameter assess vital sign , clinical examination , medical history clinical laboratory safety test ( hematology , biochemical parameter , serology urine analysis ) baseline . Adverse event monitoring do throughout study . Laboratory parameter hematology biochemistry ( except blood glucose cholesterol ) repeat end study subject .</detailed_description>
	<mesh_term>Famotidine</mesh_term>
	<criteria>Were age range 1845 year . Were neither overweight underweight correspond height per Life Insurance Corporation India height/weight chart nonmedical case . Had voluntarily give write informed consent participate study . Were normal health determine medical history physical examination subject perform within 21 day prior commencement study . There deviation regard . History hypersensitivity famotidine and/or relate group drug , include hypersensitivity H2 blocker . The subject evidence organ dysfunction clinically significant deviation normal , physical clinical determination . Investigations blood sample subject show presence disease marker HIV 1 2 , Hepatitis B C viruses syphilis infection . Investigations blood sample subject show presence value significantly different normal reference range and/or judge clinically significant haemoglobin , total white blood cell count , differential WBC count platelet count . Positive urinary screen test drug abuse ( opiates cannabinoids ) Investigations blood sample subject show presence value significantly different normal reference range and/or judge clinically significant serum creatinine , blood urea , serum aspartate aminotransferase ( AST ) , serum alanine aminotransferase ( ALT ) , serum alkaline phosphatase , serum bilirubin , plasma glucose serum cholesterol . Investigations urine sample subject show clinically abnormal chemical microscopic examination urine define presence RBC , WBC ( &gt; 4/HPF ) , epithelial cell ( &gt; 4/HPF ) , glucose ( positive ) protein ( positive ) . Clinically abnormal ECG Chest Xray . The subject history serious gastrointestinal , hepatic , renal , pulmonary , cardiovascular , neurological haematological disease , diabetes glaucoma . The subject history psychiatric illness , may impair ability provide write informed consent . The subject regular smoker smoke 10 cigarette daily difficulty abstain smoke duration study period . The subject history drug dependence excessive alcohol intake habitual basis 2 unit alcoholic beverage per day ( 1 unit equivalent half pint beer 1 glass wine 1 measure spirit ) difficulty abstain duration study period . Use enzyme modifying drug within 30 day prior Day 1 study . The subject participate clinical trial within 12 week precede Day 1 study . Subjects , completion study , would donate and/or lose 350 mL blood past 3 month . There deviation regard .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>Famotidine tablet fast study</keyword>
</DOC>